Visit https://www.peervoice.com/WJK860 to view the entire programme with slides. After completing “Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not”, participants will be able to: Define the rationale for establishing prostate-specific membrane antigen (PSMA) positivity in patients with prostate cancer before making a clinical decision on patient eligibility for a targeted radioligand therapy; Describe clinical prognostic variables that can impact treatment decisions in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy; and Use patient and disease characteristics to propose therapeutic plans that optimise clinical outcomes for patients with mCRPC who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.

Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/ZHK860 to view the entire programme with slides. After completing “Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria”, participants will be able to: Discuss the benefits and limitations of C5 inhibitors in the treatment of paroxysmal nocturnal haemoglobinuria (PNH); Differentiate between breakthrough haemolysis (BTH) and extravascular haemolysis (EVH) in patients who are receiving a terminal complement inhibitor; Evaluate clinically significant EVH in patients with PNH based on signs and symptoms; and Discuss key data on proximal complement inhibitors for the treatment of PNH and their role in clinical practice.

Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

Visit https://www.peervoice.com/RAS860 to view the entire programme with slides. After completing “Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer”, participants will be able to: Identify non-invasive molecular testing approaches to identify biomarkers of interest in patients with metastatic colorectal cancer (mCRC); Formulate individualised first-line treatment plans for patients with mCRC, based on factors such as molecular status and primary tumour location; and Assess the clinical relevance of clinical trial data evaluating novel combination therapies for the management of mCRC.

Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

Visit https://www.peervoice.com/YZV860 to view the entire programme with slides. After completing “Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?”, participants will be able to: Identify risk factors associated with toxicity development in patients with squamous cell carcinoma of the head and neck (SCCHN) who are undergoing chemoradiotherapy (CRT); Use patient and disease characteristics to determine pre-emptive approaches to reducing toxicity risk in patients with SCCHN who are to receive CRT; and Apply current recommendations for the management of CRT-associated toxicities in patients with SCCHN.

Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Visit https://www.peervoice.com/EUM860 to view the entire programme with slides. After completing “Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes”, participants will be able to: Based on the clinical data, describe what outcomes could be expected to be achieved in men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for radioligand therapy; Discuss the importance of an effective multidisciplinary team and collaboration in treatment optimisation for patients with mCRPC; Describe adverse events that may be associated with radioligand therapy in men with mCRPC; and Apply practical strategies to monitor and manage adverse events associated with radioligand therapy in men with mCRPC.

Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not

Download our free app to listen on your phone